View Older Stories View More Recent Stories

Jul 18, 2018 09:00AM Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple
Jul 13, 2018 05:54AM Amgen (AMGN), UCB Announce Re-submission of Biologics License Application (BLA) For EVENITY (romosozumab) to FDA
Jul 13, 2018 01:00AM Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA
Jun 28, 2018 04:35PM Amgen (AMGN) Highlights New Data Demonstrating Long-Term Efficacy, Safety & Tolerability of Aimovig (erenumab-aooe)
Jun 28, 2018 04:30PM Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine
Jun 27, 2018 05:00PM Amgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers
Jun 27, 2018 04:30PM Amgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Mont
Jun 27, 2018 09:04AM Amgen (AMGN) Reports Top-Line Results from Phase 3 Study Of ABP 710
Jun 27, 2018 09:00AM Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
Jun 25, 2018 05:57AM Amgen (AMGN) Announces New Data Showing Repatha (evolocumab) Significantly Reduced LDL-C & Non-HDL-C In High-risk Patients With Type 2 Diabetes
Jun 23, 2018 08:00AM New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes
Jun 19, 2018 09:03AM Amgen (AMGN) Granted EC Full Marketing Approval to Add Overall Survival Data To BLINCYTO (blinatumomab) Label
Jun 19, 2018 09:00AM Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label
Jun 11, 2018 09:01AM Amgen (AMGN) Announces FDA Approves Addition Of Positive OS Data From Phase 3 ASPIRE Trial To KYPROLIS Label
Jun 11, 2018 09:00AM FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label
Jun 8, 2018 09:02AM Amgen (AMGN) Says EC Approved Prolia for Patients With Glucocorticoid-Induced Osteoporosis
Jun 8, 2018 09:00AM European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Jun 7, 2018 04:00PM Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference
Jun 7, 2018 04:00PM /C O R R E C T I O N -- Amgen/
Jun 6, 2018 04:00PM Amgen, Oklahoma Health Care Authority And University of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes
Jun 1, 2018 04:02PM Amgen (AMGN) Reports Phase 3 A.R.R.O.W. Interim Analysis Show Positive Data from Once-Weekly KYPROLIS (carfilzomib) Regimen
Jun 1, 2018 04:00PM Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With
May 31, 2018 04:01PM Amgen (AMGN), MD Anderson Announce Collaboration To Accelerate Early Stage Oncology Therapies
May 31, 2018 04:00PM Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
May 30, 2018 04:00PM Amgen Foundation And Harvard Team Up To Offer Free Online Science Education Platform
May 23, 2018 04:01PM Amgen (AMGN), NCI Enter Pact to Improve Symptom Management During Cancer
May 23, 2018 04:00PM Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
May 22, 2018 04:45PM Amgen Announces Voting Results Of Annual Meeting Of Stockholders
May 21, 2018 04:00PM Amgen (AMGN) Reports FDA Approval of Prolia (Denosumab) For Glucocorticoid-Induced Osteoporosis
May 21, 2018 04:00PM FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
May 18, 2018 06:41AM Amgen (AMGN) Announces FDA Approval for Migraine Treatment Aimovig
May 17, 2018 07:04PM FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
May 16, 2018 09:02AM Amgen (AMGN) Announces EC Approval For Repatha To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
May 16, 2018 09:00AM Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
May 10, 2018 04:45PM Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference
Apr 30, 2018 09:01AM Amgen (AMGN) Receives Positive CHMP Opinion to Add OS Results From Phase 3 ASPIRE Study to KYPROLIS Label
Apr 30, 2018 09:00AM Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
Apr 27, 2018 09:01AM Amgen (AMGN) Announces Positive CHMP Opinion to Expand Use of Prolia to Patients With Glucocorticoid-Induced Osteoporosis
Apr 27, 2018 09:00AM Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Apr 26, 2018 01:01AM Biocartis Group NV: BIOCARTIS Q1 2018 BUSINESS UPDATE
Apr 26, 2018 01:00AM Biocartis Group NV: BIOCARTIS Q1 2018 BUSINESS UPDATE
Apr 24, 2018 04:01PM Amgen Reports First Quarter 2018 Financial Results
Apr 19, 2018 04:00PM Amgen Announces Webcast Of 2018 First Quarter Financial Results
Apr 17, 2018 04:01PM Amgen (AMGN) Presents Data at AAN Annual Reinforcing Robust, Consistent Efficacy of Aimovig For Migraine Patients With Multiple Treatment Failures
Apr 17, 2018 04:00PM Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures
Apr 10, 2018 12:14PM Amgen (AMGN) Reports Plans to Build Next Generation Biomanufacturing Plant in West Greenwich, Rhode Island
Apr 10, 2018 12:07PM Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant
Apr 9, 2018 04:01PM Amgen (AMGN) to Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies at AACR
Apr 9, 2018 04:00PM Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
Apr 3, 2018 05:46AM Amgen (AMGN) Granted European Commission Approval for Expanded Indication of XGEVA (denosumab)
View More Recent Stories View Older Stories